Post hoc analysis of SWITCH 1 and SWITCH 2 trials in types I & 2 diabetes show lower risk of hypoglycaemia with Tresiba. Novo Nordisk

According to results of a post-hoc analysis people with both type 1 and type 2 diabetes in clinical practice may achieve improved glycaemic control (HbA1c) with Tresiba (insulin degludec) from Novo Nordisk versus insulin glargine U100, without an increase in hypoglycaemia (potentially dangerous low blood sugar). The results of this new analysis from the SWITCH 1 and 2 trials were presented at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD 2018) in Berlin, Germany.

Lowering blood sugar to target levels is important to help prevent the complications of diabetes, but reductions can increase the risk of hypoglycaemia. In this post-hoc analysis, based on the reduction in hypoglycaemia risk with Tresiba found in the maintenance period of the SWITCH trials, it is estimated that people with diabetes may achieve a mean HbA1c reduction of 0.70% (type 1 diabetes) and 0.96% (type 2 diabetes) with Tresiba compared to insulin glargine U100 at similar rates of hypoglycaemia.

"Episodes of hypoglycaemia can be dangerous for people with diabetes and can often be a significant barrier to achieving glycaemic control," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "These findings add to already published evidence showing a reduced risk of hypoglycaemia with Tresiba, providing further confidence that this treatment may help people with diabetes achieve blood sugar control." This post-hoc analysis is based on patient-level data from the SWITCH 1 and 2 trials. The SWITCH trials demonstrated statistically significantly lower rates of overall symptomatic hypoglycaemia versus insulin glargine U100 in people with type 1 and type 2 diabetes.